Novelix Pharmaceuticals Limited
BSE: NOVELIX · Healthcare Research, Analytics & Technology
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Novelix Pharmaceuticals Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Start your research today
Unlock AI insights, financials, peers and live data on Novelix Pharmaceuticals Limited and 5,000+ companies — free.
Key Metrics
P/E
45.2x
Q4 FY26 · standalone
EV/EBITDA
32.1x
Q4 FY26 · standalone
NET PROFIT MARGIN
3.6%
Q4 FY26 · standalone
DEBT TO EQUITY
0.1x
Q4 FY26 · standalone
Peers · Healthcare Research, Analytics & Technology
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Novelix Pharmaceuticals LimitedNOVELIX | ₹196 Cr | 55.71 | 56.30 | — | 2.6% | 10.3% | 13.2% | +96.9% |
Indegene Ltd.INDGN | ₹13,950 Cr | 34.65 | 19.04 | 30.4% | 18.8% | 13.9% | 17.4% | +6.8% |
Suven Life Sciences LimitedSUVEN | ₹9,624 Cr | -24.51 | -27.84 | 17.3% | -557.4% | -100.5% | -99.8% | +70.6% |
Vimta LabsVIMTALABS | ₹2,759 Cr | 34.59 | 17.54 | 15.2% | 37.3% | 19.1% | 24.1% | -7.3% |
Fabtech Technologies LimitedFABTECH | ₹656 Cr | 10.68 | 8.96 | — | 16.3% | 11.6% | 14.1% | — |
Take SolutionsTAKE | ₹239 Cr | 18.77 | 38.28 | — | 7.4% | 49.8% | 24.2% | +60.9% |
As of Q4 FY26
Financials
Novelix Pharmaceuticals Limited
BSE: NOVELIX · Healthcare Research, Analytics & Technology
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Novelix Pharmaceuticals Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Start your research today
Unlock AI insights, financials, peers and live data on Novelix Pharmaceuticals Limited and 5,000+ companies — free.
Key Metrics
P/E
45.2x
Q4 FY26 · standalone
EV/EBITDA
32.1x
Q4 FY26 · standalone
NET PROFIT MARGIN
3.6%
Q4 FY26 · standalone
DEBT TO EQUITY
0.1x
Q4 FY26 · standalone
Peers · Healthcare Research, Analytics & Technology
As of Q4 FY26